Keywords
Cannabis
Aged
Medical marijuana
Neurology
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: Identify scientific studies on the use of cannabinoid derivatives in the treatment of neurological disorders in elderly patients. Methods: Integrative review of the literature on data platforms PubMED, Portal Regional Biblioteca Virtual em Saúde, and Periódicos CAPES, carried out between August and December 2023. Descriptors from the Medical Subject Headings were used: "aged", "therapeutic", "cannabis", "parkinson's disease", "epilepsy", "dementia", "bipolar disorders" and "depression" combined with the Boolean operator “AND”. Works from the last 10 years were included, without language restrictions, excluding duplicates and revisions. The initial screening was carried out by two independent evaluators, and discrepancies were resolved by consensus. Results: The final sample consisted of 25 articles, which described the use of cannabinoids for the treatment of Parkinson's disease, Alzheimer's, post-traumatic stress disorder, depression, anxiety and sleep complaints, chronic diseases (cancer, glaucoma and HIV/ AIDS), depression, frontotemporal dementia, bipolar disorder, multiple sclerosis, refractory neuropathic pruritus in amyotrophic lateral sclerosis and epilepsy. Final considerations: The discussion about the use of cannabinoids has grown, showing benefits in various neurological disorders and improving the quality of life in the elderly, but there is still a lack of studies on their effectiveness and safety.
References
BERGER M, et al. Cannabidiol for Treatment-Resistant Anxiety Disorders in Young People. The Journal of Clinical Psychiatry, 2022. Disponível em: <http://dx.doi.org/10.4088/jcp.21m14130>
BRASIL. Ministério da Saúde. Saúde da pessoa idosa. 2022. Disponível em: <https://www.gov.br/saude/pt-br/assuntos/saude-de-a-a-z/s/saude-da-pessoa-idosa/saude-da-pessoa-idosa>. Acesso em: 28 nov. 2022.
BOEHNKE KF, et al. Cannabidiol Product Dosing and Decision-Making in a National Survey of Individuals with Fibromyalgia. The Journal of Pain, 2022. Disponível em: <http://dx.doi.org/10.1016/j.jpain.2021.06.007>
BONN-MILLER MO, et al. The Long-Term, Prospective, Therapeutic Impact of Cannabis on Post-Traumatic Stress Disorder. Cannabis and Cannabinoid Research, 2022. Disponível em: <http://dx.doi.org/10.1089/can.2020.0056>
CALLÉN L, et al. Cannabinoid Receptors CB1 and CB2 Form Functional Heteromers in Brain. Journal of Biological Chemistry, 2012. Disponível em: <http://dx.doi.org/10.1074/jbc.m111.335273>
CARCUTE D e LINHARES M. Boletins: Monitoramento Pós-Mercado. Disponível em: <https://www.gov.br/anvisa/pt-br/centraisdeconteudo/publicacoes/monitoramento/boletins-monitoramento-pos-mercado>. Acesso em: 28 nov. 2022.
CASARETT DJ, et al. Benefit of Tetrahydrocannabinol versus Cannabidiol for Common Palliative Care Symptoms. Journal of palliative medicine, 2019; 22(10): 1180–1184.
DE FARIA SM, et al. Effects of acute cannabidiol administration on anxiety and tremors induced by a Simulated Public Speaking Test in patients with Parkinson’s disease. Journal of psychopharmacology , 2020; 34(2): 189–196.
FEINGOLD D, et al. Depression and anxiety among chronic pain patients receiving prescription opioids and medical marijuana. Journal of affective disorders, 2017; 218: 1–7.
GILMAN JM, et al. Effect of Medical Marijuana Card Ownership on Pain, Insomnia, and Affective Disorder Symptoms in Adults: A Randomized Clinical Trial. JAMA network open, 2022; 5(3): e222106.
GOPALAKRISHNA G, et al. Cannabinoids in the management of frontotemporal dementia: a case series. Neurodegenerative disease management, 2021; 11(1): 61–64.
HAUG NA, et al. Cannabis use patterns and motives: A comparison of younger, middle-aged, and older medical cannabis dispensary patients. Addictive behaviors, 2017; 72: 14–20.
HÄUSER W, et al. European Pain Federation (EFIC) position paper on appropriate use of cannabis-based medicines and medical cannabis for chronic pain management. European journal of pain , 2018; 22(9): 1547–1564.
KLUGER BM, et al. Cannabinoids in movement disorders. Parkinsonism & related disorders, 2022; 102: 124–130.
KUHARIC DB, et al. Cannabinoids for the treatment of dementia. Cochrane Database of Systematic Reviews, 2021. Disponível em: <http://dx.doi.org/10.1002/14651858.cd012820.pub2>
KVITLAND LR, et al. Duration of untreated illness in first-treatment bipolar I disorder in relation to clinical outcome and cannabis use. Psychiatry research, 2016; 246: 762–768.
LADINO LD, et al. Medicinal Marijuana for Epilepsy: A Case Series Study. Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques, 2014. Disponível em: <http://dx.doi.org/10.1017/cjn.2014.37>
LAND MH, et al. Effect of Cannabidiol on the Long-Term Toxicity and Lifespan in the Preclinical Model Caenorhabditis elegans. Cannabis and Cannabinoid Research, 2021. Disponível em: <http://dx.doi.org/10.1089/can.2020.0103>
LAWS JS e SMID SD Evaluating Cannabis sativa L.’s neuroprotection potential: From bench to bedside. Phytomedicine, 2022. Disponível em: <http://dx.doi.org/10.1016/j.phymed.2022.154485>
LEVY C, et al. Cannabis for Symptom Management in Older Adults. The Medical clinics of North America, 2020; 104(3): 471–489.
LI H, et al. Overview of cannabidiol (CBD) and its analogues: Structures, biological activities, and neuroprotective mechanisms in epilepsy and Alzheimer’s disease. European Journal of Medicinal Chemistry, 2020. Disponível em: <http://dx.doi.org/10.1016/j.ejmech.2020.112163>
LOU K, et al. Cannabinoids for the treatment of refractory neuropathic pruritus in amyotrophic lateral sclerosis: A case report. Palliative Medicine, 2022. Disponível em: <http://dx.doi.org/10.1177/02692163211045314>
NUGENT SM, et al. The Effects of Cannabis Among Adults With Chronic Pain and an Overview of General Harms. Annals of Internal Medicine, 2017. Disponível em: <http://dx.doi.org/10.7326/m17-0155>
PANDELIDES Z, et al. Developmental exposure to cannabidiol (CBD) alters longevity and health span of zebrafish (Danio rerio). GeroScience, 2020; 42(2): 785–800.
PANTOJA-RUIZ C, et al. Cannabis and pain: a scoping review. Brazilian Journal of Anesthesiology (English Edition), 2022. Disponível em: <http://dx.doi.org/10.1016/j.bjane.2021.06.018>
PEBALL M, et al. Non-Motor Symptoms in Parkinson’s Disease are Reduced by Nabilone. Annals of neurology, 2020; 88(4): 712–722.
ROUND JM, et al. Changes in patient health questionnaire (PHQ-9) scores in adults with medical authorization for cannabis. BMC Public Health, 2020. Disponível em: <http://dx.doi.org/10.1186/s12889-020-09089-3>
SACHEDINA F, et al. Medical cannabis use in Canada and its impact on anxiety and depression: A retrospective study. Psychiatry research, 2022; 313: 114573.
SHANNON S, et al. Cannabidiol in Anxiety and Sleep: A Large Case Series. The Permanente journal, 2019; 23: 18–041.
SHELEF A, et al. Safety and Efficacy of Medical Cannabis Oil for Behavioral and Psychological Symptoms of Dementia: An-Open Label, Add-On, Pilot Study. Journal of Alzheimer’s disease: JAD, 2016; 51(1): 15–19.
SOMMER DM, et al. Trends in the Medical Use of Synthetic Cannabinoids Among Older Adults in Ontario, Canada. Annals of internal medicine, 2020; 173(7): 589–591.
SURAEV AS, et al. An Australian nationwide survey on medicinal cannabis use for epilepsy: History of antiepileptic drug treatment predicts medicinal cannabis use. Epilepsy & behavior: E&B, 2017; 70: 334–340.
URBI B, et al. Study protocol for a randomised, double-blind, placebo-controlled study evaluating the Efficacy of cannabis-based Medicine Extract in slowing the disease pRogression of Amyotrophic Lateral sclerosis or motor neurone Disease: the EMERALD trial. BMJ open, 2019; 9(11): e029449.
VELZEBOER R, et al. Cannabis dosing and administration for sleep: a systematic review. Sleep, 2022; 45(11).
WANG Z, et al. Cannabidiol induces autophagy and improves neuronal health associated with SIRT1 mediated longevity. GeroScience, 2022. Disponível em: <http://dx.doi.org/10.1007/s11357-022-00559-7>
35.WATT G e KARL T. In vivo Evidence for Therapeutic Properties of Cannabidiol (CBD) for Alzheimer’s Disease. Frontiers in Pharmacology, 2017. Disponível em: <http://dx.doi.org/10.3389/fphar.2017.00020>
36.ZLOCZOWER, O. et al. Risk and benefit of cannabis prescription for chronic non-cancer pain. Journal of Addictive Diseases, 2022. Disponível em: <http://dx.doi.org/10.1080/10550887.2021.1956673>